Rofecoxib as adjunctive therapy for haemophilic arthropathy
- 23 March 2005
- journal article
- Published by Wiley in Haemophilia
- Vol. 11 (3), 240-244
- https://doi.org/10.1111/j.1365-2516.2005.01087.x
Abstract
Summary. Joint haemorrhage and subsequent haemophilic arthropathy are significant complications in haemophilia. The pathophysiology involves inflammation and angiogenesis. Cyclooxygenase‐2 (COX‐2) inhibitors are anti‐inflammatory agents, which have potent anti‐inflammatory, anti‐angiogenic and analgesic properties yet do not affect platelet function in the manner of traditional non‐steroidal anti‐inflammatory drugs. These properties make such agents potentially useful as adjunctive therapy in haemophilia. There is only one prior report describing rofecoxib treatment in a single haemophilia patient. Our objectives were to determine the safety and efficacy of rofecoxib in treating acute haemarthrosis, chronic synovitis, target joints and pain. We conducted a retrospective medical record review of patients treated with rofecoxib for acute haemarthrosis, chronic synovitis, target joint or pain. The safety and efficacy of rofecoxib treatment were determined based on subjective patient reports and physical examinations during follow‐up clinic visits. A total of 28 patients between 3 and 37 years of age were treated for a total of 42 courses of rofecoxib treatment. All courses were evaluated for safety and 31 for efficacy. Rofecoxib was used for eight acute haemarthrosis, four target joints, seven cases of synovitis and 12 episodes of pain. Efficacy was demonstrated particularly for chronic synovitis and pain and no serious adverse events occurred. This is the largest study to date evaluating COX‐2 inhibitors as adjunctive therapy in haemophilia and suggests that these agents may be an important adjunctive therapy in the management of haemophilia.Keywords
This publication has 17 references indexed in Scilit:
- Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control studyACC Current Journal Review, 2005
- Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate ModelClinical Cancer Research, 2004
- Prophylactic factor replacement in hemophiliaBlood Reviews, 2004
- Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxibThe American Journal of Cardiology, 2003
- The role of COX-2 in angiogenesis and rheumatoid arthritis☆Experimental and Molecular Pathology, 2003
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Haemophilia prophylaxis in young patients–a long‐term follow‐upJournal of Internal Medicine, 1997
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992
- Mortality and causes of death in Dutch haemophiliacs, 1973–86British Journal of Haematology, 1989